IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022 08:05 ET
|
IO Biotech
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022 07:30 ET
|
IO Biotech
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Second Quarter Results for 2022
August 11, 2022 17:00 ET
|
IO Biotech
Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanomaAnnounced initiation and...
IO Biotech to Participate in the 2022 BIO International Convention
June 06, 2022 08:00 ET
|
IO Biotech
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022
May 26, 2022 17:00 ET
|
IO Biotech
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech to Participate in the Jefferies Healthcare Conference
May 23, 2022 08:00 ET
|
IO Biotech
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
May 18, 2022 07:00 ET
|
IO Biotech
- First Patient Dosed in Proposed Registrational Trial in Melanoma- Multiple Sites to be Opened Across the United States, Australia, and Europe|- Trial Builds upon Phase 1 / 2 Results Recently...
IO Biotech Announces First Quarter Results for 2022
May 16, 2022 16:15 ET
|
IO Biotech
-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April -- -- Announced initiation and dosing...
IO Biotech Hosting Key Opinion Leader Webinar Series
April 22, 2022 08:33 ET
|
IO Biotech
Part 1: A New Way to Kill Tumors–IO102-IO103 Phase 3 Trial in Combination with Anti-PD-1 in Advanced Melanoma Thursday, April 28th @ 12:30pmET NEW YORK, April 22, 2022 (GLOBE NEWSWIRE) -- IO...
IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial
April 12, 2022 08:30 ET
|
IO Biotech
NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...